12,152 followers
RT @FrontOncology: New research: Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by…
RT @FrontOncology: New research: Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by…
New research: Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway: PARP inhibitors have changed the management of advanced high-grade epithelial… https://t.co/xIwy
#Bevacizumab increases the sensitivity of #olaparib to homologous recombination-proficient #ovariancancer by suppressing CRY1 via PI3K/AKT pathway https://t.co/Z5WLiTOq1y